Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells

CD4(+) T cells promote cytotoxic T lymphocyte (CTL)-mediated anticancer immune responses. We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific T(H)1 response, but also CTLs, through cross-presentation. The LP-specific T(H)1 ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yusuke, Nishimura, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850020/
https://www.ncbi.nlm.nih.gov/pubmed/24327937
http://dx.doi.org/10.4161/onci.25801
_version_ 1782294028310544384
author Tomita, Yusuke
Nishimura, Yasuharu
author_facet Tomita, Yusuke
Nishimura, Yasuharu
author_sort Tomita, Yusuke
collection PubMed
description CD4(+) T cells promote cytotoxic T lymphocyte (CTL)-mediated anticancer immune responses. We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific T(H)1 response, but also CTLs, through cross-presentation. The LP-specific T(H)1 cell responses were augmented in cancer patients vaccinated with CTL epitopes. Our findings support the clinical application of LP-based immunotherapy.
format Online
Article
Text
id pubmed-3850020
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38500202013-12-10 Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells Tomita, Yusuke Nishimura, Yasuharu Oncoimmunology Author's View CD4(+) T cells promote cytotoxic T lymphocyte (CTL)-mediated anticancer immune responses. We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific T(H)1 response, but also CTLs, through cross-presentation. The LP-specific T(H)1 cell responses were augmented in cancer patients vaccinated with CTL epitopes. Our findings support the clinical application of LP-based immunotherapy. Landes Bioscience 2013-09-01 2013-07-29 /pmc/articles/PMC3850020/ /pubmed/24327937 http://dx.doi.org/10.4161/onci.25801 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Tomita, Yusuke
Nishimura, Yasuharu
Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title_full Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title_fullStr Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title_full_unstemmed Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title_short Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
title_sort long peptide-based cancer immunotherapy targeting tumor antigen-specific cd4(+) and cd8(+) t cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850020/
https://www.ncbi.nlm.nih.gov/pubmed/24327937
http://dx.doi.org/10.4161/onci.25801
work_keys_str_mv AT tomitayusuke longpeptidebasedcancerimmunotherapytargetingtumorantigenspecificcd4andcd8tcells
AT nishimurayasuharu longpeptidebasedcancerimmunotherapytargetingtumorantigenspecificcd4andcd8tcells

Ejemplares similares